Loading patent…
Assigneet2cure GmbH
InventorsStefanie DIMMELER, Andreas M. ZEIHER, Angelika BONAUER, Carmen URBICH
Estimating the term…
The invention relates to a method for influencing the miR-92 expression in a cell, comprising the following steps: (a) providing a cell; and (b1) reducing the miR-92 expression in the cell in order to promote the vascularization or vessel repair by introducing an antisense molecule against miR-92 into the cell, or (b2) increasing the miR-92 expression in the cell for an inhibition of the tumor angiogenesis by introducing a construct into the cell, wherein said construct includes an expressible miR-92 sequence. Furthermore, the invention relates to a pharmaceutical composition, comprising an agent for reducing the miR-92 activity or expression in a cell in the form of an antisense molecule against miR-92, or an agent for increasing the miR-92 expression in a cell in the form of a construct for expressing miR-92.
A method for inhibiting angiogenesis in a subject in need thereof, wherein the method comprises increasing miR-92 expression in a cell of the subject by introducing a miR-92 molecule or by introducing a construct into the cell, wherein the construct includes an expressible miR-92 sequence, whereby the introduction of the miR-92 molecule or the construct inhibits angiogenesis.
4-6. (canceled)
(canceled)
A method for treating a disease or a condition, wherein the disease or condition is selected from the group consisting of overshooting angiogenesis, undesired angiogenesis, pathological angiogenesis, tumors, and chronic inflammations, wherein the method comprises increasing cellular miR-92 expression by introducing, into a cell, a miR-92 molecule or a construct, wherein said construct comprises an expressible miR-92 sequence.
10-20. (canceled)
Dependencies are inferred from the claim text.